In the last trading session, 1,084,903 Evogene Ltd. (NASDAQ:EVGN) shares changed hands as the company’s beta touched 0. With the company’s per share price at $4.29 changed hands at -$0.16 or -0.04% during last session, the market valuation stood at $173.95 Million. EVGN’s last price was a discount, traded about -138.7% off its 52-week high of $10.24. The share price had its 52-week low at $0.9, which suggests the last value was 79.02% up since then. When we look at Evogene Ltd.’s average trading volume, we note the 10-day average is 932.84 Million shares, with the 3-month average coming to 1.75 Million.
Analysts gave the Evogene Ltd. (EVGN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2. If we narrow down to specifics, the data shows that none out of 1 analysts rate the stock as a Sell, with a further none assigning it an Overweight rating. Of the remaining, none recommended EVGN as a Hold, 1 felt it is a Buy and none rated the stock as Underweight. Evogene Ltd.’s EPS for the current quarter is expected to be -$0.18.
Evogene Ltd. (NASDAQ:EVGN) trade information
Although EVGN has turned red as seen at the end of in last trading. With action -3.6%, the performance over the past five days has been red. The jump to weekly highs of $5.56- on Tuesday, Mar 23 added 22.8% to the stock’s daily price. The company’s shares are showing year-to-date downside of -0.09%, with the 5-day performance at -0.21% in the red. However, in the 30-day time frame, Evogene Ltd. (NASDAQ:EVGN) is -0.27% down. Looking at the short shares, we see there were 854.07 Million shares sold at short interest cover period of 488.04 days.
The consensus price target for the stock as assigned by Wall Street analysts is $15, meaning bulls need an upside of 249.65% from its current market value. According to analyst projections, EVGN’s forecast low is $15 with $15 as the target high. To hit the forecast high, the stock’s price needs a +249.65% upsurge from its current level, while the stock would need to tank 249.65% for it to hit the projected low.
Evogene Ltd. (EVGN) estimates and forecasts
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 0%. The 2021 estimates are for Evogene Ltd. earnings to increase by 16.9%, but the outlook for the next 5-year period is at 0% per year.
Evogene Ltd. (NASDAQ:EVGN)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 18.12% of Evogene Ltd. shares while 23.92% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 29.21%. There are 21 institutions holding the Evogene Ltd. stock share, with ARK Investment Management, LLC the top institutional holder. As of Dec 30, 2020, the company held 12.59% of the shares, roughly 4.59 Million EVGN shares worth $21.59 Million.
Waddell & Reed Financial Inc. holds the second largest percentage of outstanding shares, with 7.56% or 2.76 Million shares worth $12.96 Million as of Dec 30, 2020.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Among Mutual Funds, the top two as of Feb 27, 2021 were ARK ETF Tr-ARK Genomic Revolution ETF and Ivy Science & Technology Fund. With 4256807 shares estimated at $24.99 Million under it, the former controlled 11.67% of total outstanding shares. On the other hand, Ivy Science & Technology Fund held about 7.18% of the shares, roughly 2.62 Million shares worth around $12.31 Million.